{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T11:46:40Z","timestamp":1772884000370,"version":"3.50.1"},"reference-count":79,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Invasive aspergillosis (IA) crude mortality has shown a sustained reduction over the past decades, demonstrated in randomized controlled clinical trials of new antifungal agents and across large population surveys. New diagnostic tools and integrated management approaches have driven faster, more targeted initiation of appropriate antifungal therapy. In parallel, improvements in the identification of periods at highest risk for IA and in practices for management of the underlying disease processes predisposing to immunosuppression, including immunomodulatory therapies, have progressed. Given the highly complex and interconnected relationship between the underlying disease and its treatment and the predisposition to IA that the underlying disease creates, it is difficult to separate out which mortality improvements could be attributable to improved management of IA and which to better management of the underlying disease. The reductions in IA mortality have been sustained despite increases in the number of older, more vulnerable patients with more severe underlying disease undergoing treatment for acute haematological disorders and haematopoietic cell transplantation. This gradual and subtle move to a higher risk, more co-morbid patient population may have obscured any impact from the management developments other than antifungal therapy over this period, including better fungal diagnosis and supportive care. The overwhelming single factor contributing to a reduction in IA mortality over the past years appears to have been the routine adoption of mould-active antifungals, azoles in particular. Any impact of consensus definitions used to classify disease, improvements in diagnostic tools and earlier targeted strategies, remains difficult to measure based on available data. However, recently, the use of mould-active azoles has become threatened by the emergence of azole resistance in Aspergillus fumigatus, the frequent co-occurrence of Aspergillus species and Mucorales species, and difficult to handle drug\u2013drug interactions, thereby fuelling an ongoing search for novel antifungal agents.<\/jats:p>","DOI":"10.1093\/jac\/dkag077","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:30:56Z","timestamp":1771331456000},"source":"Crossref","is-referenced-by-count":0,"title":["25 years of improvement in mortality in invasive aspergillosis in haematology patients: will it be sustained or is it under threat?"],"prefix":"10.1093","volume":"81","author":[{"given":"Johan A","family":"Maertens","sequence":"first","affiliation":[{"name":"Department of Microbiology, Immunology, and Transplantation, KU Leuven , Leuven ,","place":["Belgium"]},{"name":"Department of Haematology, University Hospitals Leuven , Leuven ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6169-1920","authenticated-orcid":false,"given":"Yuri","family":"Vanbiervliet","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Transplantation, KU Leuven , Leuven ,","place":["Belgium"]},{"name":"Department of Haematology, University Hospitals Leuven , Leuven ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1517-6426","authenticated-orcid":false,"given":"Toine","family":"Mercier","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Transplantation, KU Leuven , Leuven ,","place":["Belgium"]},{"name":"Department of Haematology, AZ Sint-Maarten , Mechelen ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6337-6636","authenticated-orcid":false,"given":"Robina","family":"Aerts","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Transplantation, KU Leuven , Leuven ,","place":["Belgium"]},{"name":"Faculty of Medicine and Health Sciences, University of Antwerp , Antwerp ,","place":["Belgium"]},{"name":"Department of Pulmonary Medicine, University Hospital Antwerp , Edegem ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8668-1350","authenticated-orcid":false,"given":"Katrien","family":"Lagrou","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Transplantation, KU Leuven , Leuven ,","place":["Belgium"]},{"name":"Department of Laboratory Medicine and National Reference Centre for Mycosis, University Hospitals Leuven , Leuven ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8443-314X","authenticated-orcid":false,"given":"Monica A","family":"Slavin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Peter MacCallum Cancer Centre , Melbourne ,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"2026030611434667600_dkag077-B1","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1056\/NEJMra2027424","article-title":"Aspergillus infections","volume":"385","author":"Thompson","year":"2021","journal-title":"N Engl J Med"},{"key":"2026030611434667600_dkag077-B2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/jof9020131","article-title":"Invasive pulmonary aspergillosis","volume":"9","author":"Ledoux","year":"2023","journal-title":"J Fungi"},{"key":"2026030611434667600_dkag077-B3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/QCO.0000000000001062","article-title":"Inborn errors of immunity and invasive fungal infections: presentation and management","volume":"37","author":"Paccoud","year":"2024","journal-title":"Curr Opin Infect Dis"},{"key":"2026030611434667600_dkag077-B4","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/S2213-2600(24)00151-6","article-title":"Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patients","volume":"12","author":"Feys","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026030611434667600_dkag077-B5","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/cid\/ciab1070","article-title":"Investigational antifungal agents for invasive mycoses: a clinical perspective","volume":"75","author":"Lamoth","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026030611434667600_dkag077-B6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1055\/s-0043-1776777","article-title":"Microbiological diagnosis of pulmonary aspergillus infections","volume":"45","author":"Aerts","year":"2024","journal-title":"Semin Respir Crit Care Med"},{"key":"2026030611434667600_dkag077-B7","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/jac\/dkae158","article-title":"Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases-a debate","volume":"79","author":"Maertens","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026030611434667600_dkag077-B8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/cid\/ciae501","article-title":"Superiority trials in invasive aspergillosis: a harsh reality check with the IA-DUET (HOVON502) trial","volume":"80","author":"Lamberink","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026030611434667600_dkag077-B9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1086\/341401","article-title":"A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients","volume":"35","author":"Bowden","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2026030611434667600_dkag077-B10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"2026030611434667600_dkag077-B11","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (Ambiload trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2026030611434667600_dkag077-B12","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1093\/jac\/dkp355","article-title":"An EORTC phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients","volume":"64","author":"Viscoli","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2026030611434667600_dkag077-B13","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/bmt.2009.334","article-title":"Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: a European Organization for Research and Treatment of Cancer study","volume":"45","author":"Herbrecht","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"2026030611434667600_dkag077-B14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026030611434667600_dkag077-B15","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomized-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2026030611434667600_dkag077-B16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomized, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"2026030611434667600_dkag077-B17","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/S1473-3099(25)00224-5","article-title":"Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study","volume":"25","author":"Maertens","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026030611434667600_dkag077-B18","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1093\/cid\/ciaf185","article-title":"Fosmanogepix for the treatment of invasive mold diseases caused by Aspergillus species and rare molds: a phase 2, open-label study (AEGIS)","volume":"81","author":"Hodges","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026030611434667600_dkag077-B19","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/clinids\/23.3.608","article-title":"Therapeutic outcome in invasive aspergillosis","volume":"23","author":"Denning","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2026030611434667600_dkag077-B20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0163-4453(98)80173-4","article-title":"An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group","volume":"37","author":"Denning","year":"1998","journal-title":"J Infect"},{"key":"2026030611434667600_dkag077-B21","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/00005792-200007000-00006","article-title":"Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group","volume":"79","author":"Patterson","year":"2000","journal-title":"Medicine"},{"key":"2026030611434667600_dkag077-B22","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1086\/318483","article-title":"Aspergillosis case-fatality rate: systematic review of the literature","volume":"32","author":"Lin","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2026030611434667600_dkag077-B23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1086\/323335","article-title":"Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus","volume":"34","author":"Ascioglu","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2026030611434667600_dkag077-B24","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026030611434667600_dkag077-B25","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026030611434667600_dkag077-B26","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/cid\/ciu911","article-title":"Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group","volume":"60","author":"Herbrecht","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026030611434667600_dkag077-B27","doi-asserted-by":"publisher","first-page":"ofae094","DOI":"10.1093\/ofid\/ofae094","article-title":"Patterns and drivers of antifungal prescribing in acute leukemia: a retrospective cohort study","volume":"11","author":"Houston","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026030611434667600_dkag077-B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12919-023-00285-8","article-title":"Rethinking the pros and cons of randomized controlled trials and observational studies in the era of big data and advanced methods: a panel discussion","volume":"18","author":"Fernainy","year":"2024","journal-title":"BMC Proc"},{"key":"2026030611434667600_dkag077-B29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41409-019-0624-z","article-title":"Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors","volume":"55","author":"Styczy\u0144ski","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"2026030611434667600_dkag077-B30","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001\u20132006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2026030611434667600_dkag077-B31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1086\/510592","article-title":"Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality","volume":"44","author":"Upton","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2026030611434667600_dkag077-B32","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter prospective antifungal therapy (PATH) alliance registry","volume":"48","author":"Neofytos","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2026030611434667600_dkag077-B33","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3324\/haematol.2001.172536","article-title":"Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA infection program","volume":"86","author":"Pagano","year":"2001","journal-title":"Haematologica"},{"key":"2026030611434667600_dkag077-B34","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1182\/blood.v106.11.4556.4556","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"2026030611434667600_dkag077-B35","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1086\/522189","article-title":"Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study\u2013Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne","volume":"45","author":"Pagano","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2026030611434667600_dkag077-B36","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3324\/haematol.2009.012054","article-title":"Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study","volume":"95","author":"Pagano","year":"2010","journal-title":"Haematologica"},{"key":"2026030611434667600_dkag077-B37","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/jac\/dky550","article-title":"Real-life\u2019 analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study","volume":"74","author":"Del Principe","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026030611434667600_dkag077-B38","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/myc.13384","article-title":"Invasive aspergillosis in relapsed\/refractory acute myeloid leukaemia patients: results from SEIFEM 2016-B survey","volume":"65","author":"Del Principe","year":"2022","journal-title":"Mycoses"},{"key":"2026030611434667600_dkag077-B39","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1111\/j.1469-0691.2011.03548.x","article-title":"Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005\u20132007)","volume":"17","author":"Lortholary","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2026030611434667600_dkag077-B40","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/1469-0691.12002","article-title":"Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil","volume":"19","author":"Nucci","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"2026030611434667600_dkag077-B41","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.bbmt.2015.03.018","article-title":"Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study","volume":"21","author":"Sun","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026030611434667600_dkag077-B42","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ijantimicag.2016.10.019","article-title":"Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA study","volume":"49","author":"Koehler","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2026030611434667600_dkag077-B43","doi-asserted-by":"publisher","first-page":"e0186422","DOI":"10.1371\/journal.pone.0186422","article-title":"Clinical outcome and prognostic factors associated with invasive pulmonary aspergillosis: an 11-year follow-up report from Taiwan","volume":"12","author":"Sun","year":"2017","journal-title":"PLoS ONE"},{"key":"2026030611434667600_dkag077-B44","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/cid\/ciae612","article-title":"Invasive fungal disease in patients undergoing allogeneic hematopoietic stem cell transplantation in China: a multicenter epidemiological study (CAESAR 2.0)","volume":"80","author":"Li","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026030611434667600_dkag077-B45","author":"Dixon"},{"key":"2026030611434667600_dkag077-B46","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"2026030611434667600_dkag077-B47","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"2026030611434667600_dkag077-B48","doi-asserted-by":"publisher","first-page":"ofaf709","DOI":"10.1093\/ofid\/ofaf709","article-title":"Triazoles versus echinocandins for the first-line treatment of invasive pulmonary aspergillosis: a propensity score-weighted multicenter study","volume":"12","author":"Hatzl","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026030611434667600_dkag077-B49","doi-asserted-by":"publisher","first-page":"i29","DOI":"10.1093\/jac\/dkx031","article-title":"Clinical considerations in the early treatment of invasive mould infections and disease","volume":"72","author":"Mercier","year":"2017","journal-title":"J Antimicrobial Chemother"},{"key":"2026030611434667600_dkag077-B50","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1093\/mmy\/myw114","article-title":"Invasive aspergillosis in acute myeloid leukemia: are we making progress in reducing mortality?","volume":"55","author":"Dragonetti","year":"2017","journal-title":"Med Mycol"},{"key":"2026030611434667600_dkag077-B51","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/jac\/dkx423","article-title":"Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial","volume":"73","author":"Kontoyiannis","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026030611434667600_dkag077-B52","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1086\/509917","article-title":"Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign","volume":"44","author":"Greene","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2026030611434667600_dkag077-B53","doi-asserted-by":"publisher","first-page":"CD007394","DOI":"10.1002\/14651858.CD007394.pub2","article-title":"Galactomannan detection for invasive aspergillosis in immunocompromised patients","volume":"2015","author":"Leeflang","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2026030611434667600_dkag077-B54","doi-asserted-by":"publisher","first-page":"CD009551","DOI":"10.1002\/14651858.CD009551.pub4","article-title":"Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people","volume":"9","author":"Cruciani","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2026030611434667600_dkag077-B55","doi-asserted-by":"publisher","first-page":"e34569","DOI":"10.1016\/j.heliyon.2024.e34569","article-title":"Diagnostic accuracy of galactomannan and lateral flow assay in invasive aspergillosis: a diagnostic meta-analysis","volume":"10","author":"Zhang","year":"2024","journal-title":"Heliyon"},{"key":"2026030611434667600_dkag077-B56","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s00134-024-07341-7","article-title":"Invasive fungal diseases in adult patients in intensive care unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM","volume":"50","author":"Bassetti","year":"2024","journal-title":"Intensive Care Med"},{"key":"2026030611434667600_dkag077-B57","doi-asserted-by":"publisher","first-page":"e43347","DOI":"10.1371\/journal.pone.0043347","article-title":"Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis","volume":"7","author":"Zou","year":"2012","journal-title":"PLoS ONE"},{"key":"2026030611434667600_dkag077-B58","doi-asserted-by":"publisher","first-page":"CD013604","DOI":"10.1002\/14651858.CD013604.pub2","article-title":"Pre-emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer","volume":"11","author":"Uneno","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2026030611434667600_dkag077-B59","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/cid\/ciac623","article-title":"Empiric vs preemptive antifungal strategy in high-risk neutropenic patients on fluconazole prophylaxis: a randomized trial of the European Organization for Research and Treatment of Cancer","volume":"76","author":"Maertens","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026030611434667600_dkag077-B60","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/myc.13056","article-title":"Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: an EFISG, IDWP-EBMT, EORTC-IDG and SEIFEM survey","volume":"63","author":"Lanternier","year":"2020","journal-title":"Mycoses"},{"key":"2026030611434667600_dkag077-B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2025.10.017","article-title":"Laboratory innovations to diagnose invasive mould infections\u2014what is relevant, what is not?","author":"Vanbiervliet","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"2026030611434667600_dkag077-B62","doi-asserted-by":"publisher","first-page":"CD008238","DOI":"10.1002\/14651858.CD008238.pub3","article-title":"Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia","volume":"6","author":"Gurion","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2026030611434667600_dkag077-B63","doi-asserted-by":"publisher","first-page":"dkaf473","DOI":"10.1093\/jac\/dkaf473","article-title":"Redefining antifungal prophylaxis in acute leukaemia in the era of targeted therapies","volume":"81","author":"Nucci","year":"2026","journal-title":"J Antimicrob Chemother"},{"key":"2026030611434667600_dkag077-B64","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/QCO.0000000000000662","article-title":"Aspergillus fumigatus and pan-azole resistance: who should be concerned?","volume":"33","author":"Wiederhold","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"2026030611434667600_dkag077-B65","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1093\/cid\/ciy859","article-title":"Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective cohort study","volume":"68","author":"Lestrade","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026030611434667600_dkag077-B66","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1093\/jac\/dkz258","article-title":"Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients","volume":"74","author":"Resendiz-Sharpe","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026030611434667600_dkag077-B67","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1093\/jac\/dkv177","article-title":"High prevalence of azole resistance in Aspergillus fumigatus isolates from high-risk patients","volume":"70","author":"Fuhren","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2026030611434667600_dkag077-B68","doi-asserted-by":"publisher","first-page":"2400559","DOI":"10.2807\/1560-7917.ES.2025.30.18.2400559","article-title":"Doubling of triazole resistance rates in invasive aspergillosis over a 10-year period, Belgium, 1 April 2022 to 31 March 2023","volume":"30","author":"Cuypers","year":"2025","journal-title":"Euro Surveill"},{"key":"2026030611434667600_dkag077-B69","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","article-title":"International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus","volume":"21\u201322","author":"Verweij","year":"2015","journal-title":"Drug Resist Updat"},{"key":"2026030611434667600_dkag077-B70","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1186\/s12879-024-10143-3","article-title":"Review of the novel antifungal drug olorofim (F901318)","volume":"24","author":"Vanbiervliet","year":"2024","journal-title":"BMC Infect Dis"},{"key":"2026030611434667600_dkag077-B71","doi-asserted-by":"publisher","first-page":"e59210","DOI":"10.7759\/cureus.59210","article-title":"Fosmanogepix: the novel anti-fungal agent\u2019s comprehensive review of in vitro, in vivo, and current insights from advancing clinical trials","volume":"16","author":"Almajid","year":"2024","journal-title":"Cureus"},{"key":"2026030611434667600_dkag077-B72","doi-asserted-by":"publisher","first-page":"1080921","DOI":"10.3389\/fcimb.2022.1080921","article-title":"Blood Mucorales PCR to track down Aspergillus and Mucorales co-infections in at-risk hematology patients: a case-control study","volume":"12","author":"Aerts","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"2026030611434667600_dkag077-B73","doi-asserted-by":"publisher","first-page":"e0120125","DOI":"10.1128\/jcm.01201-25","article-title":"Molecular diagnostics in cancer patients with suspected respiratory mold infections","volume":"63","author":"Rickerts","year":"2025","journal-title":"J Clin Microbiol"},{"key":"2026030611434667600_dkag077-B74","doi-asserted-by":"publisher","first-page":"ofaf801","DOI":"10.1093\/ofid\/ofaf801","article-title":"Mucorales PCR testing in respiratory and biopsy samples from immunocompromised patients with invasive pulmonary aspergillosis and other mold infections: results from a multicenter ECMM study","volume":"13","author":"Sedik","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026030611434667600_dkag077-B75","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/jac\/dkae103","article-title":"Triazole antifungal drug interactions-practical considerations for excellent prescribing","volume":"79","author":"Lewis","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026030611434667600_dkag077-B76","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1002\/cncr.35251","article-title":"Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"130","author":"Dinh","year":"2024","journal-title":"Cancer"},{"key":"2026030611434667600_dkag077-B77","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jinf.2019.04.002","article-title":"Development and internal validation of a model for predicting 60-day risk of invasive mould disease in patients with haematological malignancies","volume":"78","author":"Stanzani","year":"2019","journal-title":"J Infect"},{"key":"2026030611434667600_dkag077-B78","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41409-022-01879-0","article-title":"First-line steroid-free systemic treatment of acute and chronic graft-versus-host disease after novel prophylaxis regimens","volume":"58","author":"Moiseev","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"2026030611434667600_dkag077-B79","doi-asserted-by":"publisher","first-page":"e70104","DOI":"10.1111\/tid.70104","article-title":"The changing epidemiology of breakthrough invasive fungal disease in allogeneic hematopoietic stem cell transplant recipients in the era of modified-release posaconazole prophylaxis","volume":"27","author":"Tio","year":"2025","journal-title":"Transpl Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/4\/dkag077\/67260022\/dkag077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/4\/dkag077\/67260022\/dkag077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:43:52Z","timestamp":1772815432000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag077\/8509389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag077","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,3,4]]},"article-number":"dkag077"}}